



New evidence continues to emerge showing how Optiflow™ Nasal High Flow contributes to **improved patient care and outcomes.**

Predicting the outcome of nasal high flow therapy using the Respiratory Rate and Oxygenation (ROX) index



Author*: Stanislav Tatkov, M.D., Ph.D.

Background

In the last decade nasal high flow (NHF) has become a first-line therapy for patients with acute hypoxemic respiratory failure.¹

NHF can be a powerful oxygenation tool.² However, a high FiO₂ can potentially mask deterioration and delay escalation of care.




Figure 1. Patients who were intubated after more than 2 days on NHF had a higher mortality rate.⁵

The risk of delayed intubation

The risk of invasive mechanical ventilation is well understood, although delaying intubation can result in a lengthened hospital stay and increased mortality.^{3,4} In a retrospective study by *Kang et al.*, patients receiving NHF therapy who were intubated earlier had lower mortality, improved extubation success, and fewer days on a ventilator (Figure 1).⁵

* Clinical Research Manager, Fisher & Paykel Healthcare

How to predict success and failure of NHF using ROX

What is ROX?

Roca and colleagues (2016) first established the ROX index to predict the success of NHF therapy.⁶ The ROX index combines three common measurements: FiO₂, SpO₂ and respiratory rate (Figure 2). **NHF of 50 L/min and higher** in adults exceeds inspiratory flow and reduces the entrainment of air. This makes delivered FiO₂ more precise, which may result in a more accurate ROX calculation. The index is based on two well-known facts: sicker patients require more oxygen and have a higher respiratory rate.⁷




Figure 2. The ROX index, followed by examples from a healthy subject and a patient with respiratory failure.

Validating ROX

The index has been validated in a multi-center prospective study on 191 patients with pneumonia.⁸

The authors confirmed that a ROX value of ≥ 4.88 predicted the success of NHF.

In addition, ROX values were provided that predict NHF failure with a high specificity (98–99%): ≤ 2.85 at 2 hours, ≤ 3.47 at 6 hours, and ≤ 3.85 at 12 hours of NHF use (Figure 3).



Figure 3. The ROX index value that predicts failure shown in red at 2, 6 and 12 hours and the ROX index value that predicts success above 4.88.

The importance of FiO₂

Among components of the index, SpO₂/FiO₂ had a greater weight than the respiratory rate.⁸ This is reflected in Figure 4: an FiO₂ of 0.80 or above will predict a ROX index of less than 4.88 (shown in red) and an FiO₂ of 0.50 or below will predict a higher ROX (shown in blue).




Figure 4. ROX values above 4.88 are shown in blue and below 4.88 are shown in red. FiO₂ below 0.50 predicts higher ROX and above 0.80, lower ROX for breathing rates between 25 and 40 breaths/min and SpO₂ of 95%.

What do changes in the ROX mean?

If the respiratory rate and/or FiO_2 requirement is increasing, then the patient is clearly deteriorating. The continuous monitoring of ROX may be particularly helpful when the patient is in an unstable condition.⁸ For example, two patients begin NHF treatment and both have a ROX value of 4.0 (see table below and Figure 5). Because this is only the start of the therapy, the ROX value can be monitored to see whether the index improves.

During the first 6 hours, **Patient 1** has a decrease in respiratory rate and the FiO_2 has been lowered; **Patient 2** has an increase in respiratory rate and the FiO_2 has been increased. As a result, the ROX value at 6 hours for **Patient 1** is 6.0 and for **Patient 2** it is 3.0. Based on the values provided by Roca et al.,⁸ **Patient 1** has a high likelihood of NHF therapy success and can be maintained on NHF. However, **Patient 2** has a trending decline and low ROX. Therefore, escalation of care should be considered.

Patient 1						Patient 2					
No.	Date/time	SpO_2 (%)	FiO_2	RR (min-1)	ROX	No.	Date/time	SpO_2 (%)	FiO_2	RR (min-1)	ROX
1	initiation	95	0.70	34	4.0	1	initiation	95	0.75	32	4.0
2	2	95	0.60	32	5.0	2	2	95	0.80	34	3.5*
3	6	95	0.50	32	6.0	3	6	95	0.85	37	3.0
4	12	95	0.45	30	7.0	4	12	Therapy escalated			

* Even though a ROX index value of 3.5 at 2 hours would not indicate failure, the ROX index value has decreased since therapy initiation, indicating that escalation of care should be considered.

ROX vector

Combining the ROX values with the change in the respiratory rate and FiO_2 can indicate whether escalation is required. A proposed XY plot of the key components of ROX may show

the direction of changes in vector form (see arrows in Figure 5 below).⁹ Vectors towards the upper right indicate a deterioration and, towards the lower left, an improvement.




Figure 5. XY plot between respiratory rate and FiO_2 . The blue arrows in a vector form demonstrate a change towards NHF success and the red arrows demonstrate the change towards NHF failure. The dotted line shows the values for ROX at 4.88 and the SpO_2 of 95%.

Putting ROX into practice

The ROX index is a useful tool because it requires only a few data points and can be measured at the patient's bedside. The index can be used to monitor the patient and predict the likelihood of success or failure of NHF therapy. Furthermore, ROX highlights the importance of the required FiO_2 – if the required FiO_2 is high, then the patient may be at greater risk of failure.

ROX Vector App

Download the ROX Vector App on your device to calculate the ROX index and plot vectors. Available on the App Store and Google Play.



1. Rochweg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. *Intensive Care Medicine*. 2019 May;45(5):563-572. [PubMed PMID: 30888444](#).
2. Masclans JR, Perez-Teran P, Roca O. The role of high-flow oxygen therapy in acute respiratory failure. *Medicina intensiva*. 2015 Nov;39(8):505-15. [PubMed PMID: 26429697](#).
3. Bauer PR, Gajic O, Nanchal R, Kashyap R, Martin-Loeches I, Sakr Y, et al. Association between timing of intubation and outcome in critically ill patients: A secondary analysis of the ICON audit. *Journal of Critical Care*. 2017 Dec;42:1-5. [PubMed PMID: 28641231](#).
4. Kangelaris KN, Ware LB, Wang CY, Janz DR, Zhuo H, Matthay MA, et al. Timing of Intubation and Clinical Outcomes in Adults With Acute Respiratory Distress Syndrome. *Critical Care Medicine*. 2016 Jan;44(1):120-9. [PubMed PMID: 26474112](#).
5. Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. *Intensive Care Medicine*. 2015 Apr;41(4):623-32. [PubMed PMID: 25691263](#).
6. Roca O, Messika J, Caralt B, Garcia-de-Acilu M, Sztymf B, Ricard JD, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. *Journal of Critical Care*. 2016 Oct;35:200-5. [PubMed PMID: 27481760](#).
7. Tatkov S. Nasal High-Flow Therapy: Role of FiO_2 in the ROX Index. *American Journal of Respiratory and Critical Care Medicine*. 2019 Jul 1;200(1):115-6. [PubMed PMID: 30896967](#).
8. Roca O, Caralt B, Messika J, Samper M, Sztymf B, Hernandez G, et al. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy. *American Journal of Respiratory and Critical Care Medicine*. 2019 Jun 1;199(11):1368-76. [PubMed PMID: 30576221](#).
9. Tatkov S. ROX vector to complement ROX index during nasal high flow therapy of hypoxemic patients. *Journal of Critical Care*. 2019 Aug 27. [PubMed PMID: 31635954](#).

Any clinical opinions in this newsletter are the opinions of the contributing authors and are given for information purposes only. The clinical opinions are not intended as – and do not – substitute medical advice. F&P and Optiflow are trademarks of Fisher & Paykel Healthcare Limited. For patent information, see fphcare.com/ip